鲍勃·尼尔森

2023年7月18日

拱Venture Partners,长期投资公司,近年来一直致力于支持生物技术与宏伟的计划,也发表了一些最好的回报外部投资者的钱,据统计2023年版的年度排名生物技术风险投资的表现。广告拱层顶部的统计并不陌生的VC排名,但今年它进入。阿尔塔合作伙伴和旗舰开拓性的名单上排名第二和第三。拱是最经验丰富的生物技术风险投资公司之一。在芝加哥成立30多年前,仍然是由两名创始人:鲍勃·尼尔森和基斯克兰德尔。一个成功的风险投资公司会承诺三一个投资者的钱。计数,拱了:每一个美元,第三方——大学教师工会养老基金投资机构或拱了投资于生物技术创业公司,该公司将在1.26美元和5.15美元之间。广告公司已投资于各种各样的创业公司,从公司做血液测试,寻找癌症的早期迹象生物基因药物开发人员生产设施。统计的排名是基于获得的数据通过公共记录请求和反映公司附近的状态结束的前一年,在2023年的报告中,2022年9月。2022年的数据突显出市场低迷持续紧张的迹象,以及拱的持续强劲的回报在忙。 The report assesses 18 firms that invest in biotech companies, in addition to upcoming fundraisings, notable deals, and new hires. ARCH, for one, brought in four new venture partners in the last year. Frazier Life Sciences joined STAT’s ranking this year, sliding into the 16th spot on the list. The group is part of Frazier Healthcare Partners, a Seattle-based private equity firm that invests in early-stage startups and growing health care companies, while also acquiring ownership stakes in established commercial companies that it can retool. Firms often set a 10-year lifespan for an individual fund, giving them time to scout out startups, invest the money, and wait for those companies to reach a financial inflection point like an IPO or acquisition that will enable investors to reap their proceeds. ARCH has several decade-old funds that have performed exceedingly well, including its 7th and 8th funds which, respectively, quintupled and tripled investors’ money. Meanwhile, Frazier’s sixth fund, which was raised in 2007, the same year that ARCH raised its 7th fund, returned $1.50 for every dollar that was invested. ARCH’s return results are generally in line with what was reported for ARCH in STAT’s 2022 rankings report. But the slowdown in IPOs, a tougher stock market, and rising interest rates tripped up some other firms, allowing ARCH to pull ahead in the ranking. (ARCH was an early investor in one of the few biotechs to go public in the last 12 months, the genetic editing company Prime Medicine.) Nelsen told STAT that ARCH’s team doesn’t watch how its investments are performing with an eagle eye. They only analyze the data when they set out to raise a new fund, as the firm did in both 2021 and 2022 , and instead focus on the startups they’re developing. “Numbers, especially unrealized returns, come and go. We focus on the fundamentals of investing in great platform science that can prevent disease or make curative or disease-modifying medicines. Make progress in fixing disease and you will make money eventually,” Nelsen said. Kate Sheridan contributed reporting.